U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

1997
189
Substance Class Protein
Created
by admin
on Mon Mar 31 18:30:06 GMT 2025
Edited
by admin
on Mon Mar 31 18:30:06 GMT 2025
Protein Sub Type
Sequence Type COMPLETE
Record UNII
382L14738L
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
COAGULATION FACTOR IX RECOMBINANT HUMAN
Common Name English
NONACOG ALFA
EMA EPAR   INN   MART.   USAN   WHO-DD  
USAN   INN  
Preferred Name English
BENEFIX
Brand Name English
nonacog alfa [INN]
Common Name English
NONACOG ALFA [USAN]
Common Name English
NONACOG GAMMA [JAN]
Common Name English
COAGULATION FACTOR IX (RECOMBINANT)
Common Name English
NONACOG ALFA [JAN]
Common Name English
Nonacog alfa [WHO-DD]
Common Name English
FACTOR IX,RECOMBINANT
VANDF  
Common Name English
RECOMBINANT FACTOR IX
Common Name English
NONACOG GAMMA
INN  
Official Name English
RIXUBIS
Brand Name English
NONACOG ALFA [MART.]
Common Name English
FACTOR IX,RECOMBINANT [VANDF]
Common Name English
Nonacog gamma [WHO-DD]
Common Name English
nonacog gamma [INN]
Official Name English
NONACOG ALFA [EMA EPAR]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS BENEFIX (AUTHORIZED: HEMOPHILIA B)
Created by admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
WHO-ATC B02BD09
Created by admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
FDA ORPHAN DRUG 82294
Created by admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
FDA ORPHAN DRUG 377412
Created by admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
WHO-VATC QB02BD09
Created by admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
NDF-RT N0000184169
Created by admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
Code System Code Type Description
CAS
181054-95-5
Created by admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
GENERIC (FAMILY)
ChEMBL
CHEMBL2109205
Created by admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
PRIMARY
DRUG CENTRAL
5163
Created by admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
PRIMARY
DAILYMED
382L14738L
Created by admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
PRIMARY
NCI_THESAURUS
C82270
Created by admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
PRIMARY
DRUG BANK
DB00100
Created by admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
PRIMARY
INN
7607
Created by admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
PRIMARY
FDA UNII
382L14738L
Created by admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
PRIMARY
UNIPROT
P00740
Created by admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
PRIMARY
EVMPD
SUB03451MIG
Created by admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
PRIMARY
SMS_ID
100000089406
Created by admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
PRIMARY
RXCUI
1300488
Created by admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
PRIMARY
USAN
HH-12
Created by admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
PRIMARY
NDF-RT
N0000175979
Created by admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
PRIMARY Increased Coagulation Activity [PE]
NDF-RT
N0000007914
Created by admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
PRIMARY Blood Coagulation Factors [Chemical/Ingredient]
From To
1_26 1_42
1_109 2_132
1_156 1_170
1_181 1_209
2_18 2_23
2_51 2_62
2_56 2_71
2_73 2_82
2_88 2_99
2_95 2_109
2_111 2_124
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
O 2_53
O 2_61
Related Record Type Details
COAGULATION FACTOR IX RECOMBINANT HUMAN
ACTIVE MOIETY

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO ACID SUBSTITUION [2_68] SERINE Amount: DEXFOSFOSERINE VI4F0K069V
AMINO ACID SUBSTITUION [2_64] ASPARTIC ACID Amount: .BETA.-HYDROXY-L-ASPARTIC ACID, ERYTHRO- GDV0MSK2SG
AMINO ACID SUBSTITUION [2_7] [2_8] [2_15] [2_17] [2_18] [2_21] [2_26] [2_27] [2_30] [2_33] [2_36] [2_40] GLUTAMIC ACID Amount: .GAMMA.-CARBOXYGLUTAMIC ACID 16FQV4RZKL
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966